Ownership and insider activity for Monte Rosa Therapeutics, Inc. (GLUE): insider transactions, US Senate and House trading disclosures and shares outstanding. Track how corporate insiders and politicians are trading the stock.
Monte Rosa Therapeutics, Inc. is a biopharmaceutical company dedicated to pioneering novel, small-molecule precision medicines. Their core approach involves leveraging the body's inherent mechanisms to precisely eliminate therapeutically relevant proteins. Among their key initiatives is an oral molecular glue degrader designed to target GSPT1, a specific translational termination factor and degron-containing protein, with the aim of treating Myc-driven cancers.
Price
| Price | $12.60 |
| Market Cap | $1.1B |
| Exchange | NASDAQ |
| Country | US |
Recent Insider Transactions
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 2026-07-16 | Warmuth Markus | S-Sale | 9,500 | $220K |
| 2026-07-15 | Champoux Jennifer | M-Exempt | 4,351 | $17K |
| 2026-07-15 | Champoux Jennifer | S-Sale | 4,351 | $102K |
| 2026-07-15 | Champoux Jennifer | M-Exempt | 4,351 | $17K |
| 2026-07-06 | Townson Sharon | M-Exempt | 6,000 | $37K |
| 2026-07-06 | Townson Sharon | M-Exempt | 6,000 | $37K |
| 2026-07-06 | Townson Sharon | S-Sale | 5,600 | $130K |
| 2026-07-06 | Townson Sharon | S-Sale | 400 | $10K |
| 2026-07-01 | Behbahani Ali | J-Other | 1,000,000 | |
| 2026-07-01 | Behbahani Ali | J-Other | 15,000 |
Balance Sheet (10y)
| Year | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $6.0M | $41.7M | $346.1M | $54.9M | $128.1M | $224.3M | $129.9M |
| Short-term Investments | 0 | 0 | 0 | $207.9M | $104.3M | $147.9M | $247.2M |
| Receivables | 0 | 0 | 0 | $7.7M | $505000 | $173000 | $4.6M |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Current Assets | $9.8M | $43.6M | $348.7M | $275.9M | $236.2M | $377.4M | $393.2M |
| Property, Plant & Equipment | $1.3M | $4.6M | $12.3M | $61.9M | $62.6M | $56.3M | $50.4M |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Assets | $11.1M | $49.4M | $366.3M | $342.4M | $303.8M | $438.7M | $448.7M |
| Accounts Payable | $3.2M | $7.1M | $6.6M | $7.9M | $11.2M | $17.2M | $3.5M |
| Short-term Debt | $750000 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Current Liabilities | $4.3M | $29.3M | $16.6M | $25.6M | $46.6M | $156.9M | $64.2M |
| Long-term Debt | 0 | $67.8M | 0 | 0 | 0 | 0 | $34.8M |
| Total Liabilities | $23.2M | $98.1M | $18.8M | $71.0M | $124.5M | $215.8M | $215.6M |
| Retained Earnings | -$12.2M | -$48.1M | -$122.0M | -$230.5M | -$365.9M | -$438.6M | -$477.2M |
| Total Equity | -$12.1M | -$48.7M | $347.5M | $271.4M | $179.2M | $222.9M | $233.1M |
| Total Debt | $750000 | $67.8M | 0 | $47.0M | $46.0M | $42.7M | $39.2M |
| Net Debt | -$5.2M | $26.1M | -$346.1M | -$215.8M | -$186.4M | -$329.4M | -$337.9M |
| Working Capital | $5.5M | $14.3M | $332.0M | $250.3M | $189.6M | $220.5M | $329.0M |
Financial Health
| Debt / Equity | 0.08 |
| Current Ratio | 9.52 |
Profitability
| Return on Equity | -43.31% |
| Return on Invested Capital | -28.19% |
| Return on Assets | -23.15% |
| Gross Margin | 92.94% |
| Operating Margin | -633.04% |
| Net Margin | -560.85% |
Related companies: ARVN · AVBP · DAWN · DNA · GERN · MGTX · REPL
Explore sector: Healthcare · Biotechnology
More sections of GLUE: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks